大株红景天注射液联合低分子肝素治疗不稳定型心绞痛的效果观察

摘要

目的 观察大株红景天注射液联合低分子肝素治疗不稳定型心绞痛(UAP)的临床效果及安全性.方法 选择2012年1月至2014年5月解放军第八六医院收治的UAP患者100例,完全随机分为观察组(50例)和对照组(50例).对照组给予常规和对症治疗;观察组在常规和对症治疗基础上加用大株红景天注射液联合低分子肝素治疗.观察2组治疗7d后临床疗效、心绞痛发作频次与持续时间、心电图改善情况.结果 观察组患者总有效率高于对照组,2组比较差异有统计学意义[92.0％(46/50)比72.0％(36/50),P＜0.05].观察组心绞痛发作频次:治疗前(16.7±1.2)次/周,治疗后(3.8±0.5)次/周;发作持续时间:治疗前(15.2 ±2.9) min,治疗后(4.5±0.7) min.对照组心绞痛发作频次:治疗前(16.8±1.4)次/周,治疗后(7.7±1.2)次/周;发作持续时间:治疗前(14.9±3.5) min,治疗后(6.9 ±0.9) min.上述指标2组间治疗后比较差异有统计学意义(P＜0.05).观察组患者心电图改善率为48.0％(24/50),对照组为24.0％(12/50),2组比较差异有统计学意义(P＜0.05).结论 大株红景天注射液联合低分子肝素治疗UAP可改善心绞痛症状,缩短心绞痛发作持续时间,且安全有效.%Objective To observe the clinical efficacy and safety of Soften injection combined with low molecular weight heparin in treatment of unstable angina pectoris (UAP).Methods A total of 100 patients with UAP from January 2012 to May 2014 were enrolled and randomly divided into observation group (50 cases) and control group (50 cases).All the patients received conventional and symptomatic treatment;the patients in observation group were additionally administrated with sofren injection combined with low molecular weight hepa rin.The clinical curative effect,frequency and duration of angina attack,ECG improvement were assessed and compared between two groups 7 days after treatment.Results The clinical efficacy of observation group was significantly higher than that of control group [92.0％ (46/50) vs 72.0％ (36/50),P ＜ 0.05].Before treatment,the frequency and duration of angina attack was (16.7 ± 1.2) times per week and (15.2 ± 2.9) min in observe group;it was (16.8 ± 1.4) times per week and (14.9 ± 3.5) min in control group.After treatment,the angina attack frequency and duration was (3.8 ± 0.5) times per week and (4.5 ± 0.7) min in observe group,which were both significantly lower than those in control group [(7.7 ± 1.2) times per week and (6.9 ± 0.9) min,respectively,both P ＜ 0.05].The improvement rate of ECG in observe group was statistical higher than that in control group [48.0 (24/50) vs 24.0％ (12/50),P ＜ 0.05].Conclusion Sofren injection combined with low molecular weight heparin can effectively and safely improve the angina symptoms and shorten the attack duration in treatment of UAP.